ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmacyclics has signed a drug development deal with Johnson & Johnson’s Janssen Biotech unit. The two companies will develop Pharmacyclics’ PCI-32765, an oral Bruton’s tyrosine kinase inhibitor targeting hematological cancers. The compound is now in Phase II clinical trials. Janssen will pay Pharmacyclics $150 million up front, and the biotech firm could receive up to $825 million more in milestone payments. The companies will also split efforts to develop PCI-32765 in other disease areas.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter